INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09969 INNOCARE

Not Yet Opened 02-03 16:08:20

11.260

-0.250

-2.17%

High11.640	Low11.010	Vol8.55M
Open11.640	D1 Closing11.510	Amplitude5.47%
Mkt Cap19.84B	Tradable Cap16.82B	Total Shares1.76B
T/O95.94M	T/O Rate0.57%	Tradable Shares1.49B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"INNOCARE","latestPrice":11.26,"timestamp":1770106100010,"preClose":11.51,"halted":0,"volume":8554434,"delay":0,"changeRate":-0.021720243266724587,"floatShares":1494000000,"shares":1762000000,"eps":-0.27,"marketStatus":"Not Yet Opened","change":-0.25,"latestTime":"02-03 16:08:20","open":11.64,"high":11.64,"low":11.01,"amount":95942811,"amplitude":0.054735,"askPrice":11.27,"askSize":4000,"bidPrice":11.26,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.143,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":0,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":11.51,"openAndCloseTimeList":[[1770082200000,1770091200000],[1770094800000,1770105600000]],"volumeRatio":0.769154,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"Innocare Pharma Limited","latestPrice":21.13,"timestamp":1770102000000,"preClose":21.96,"halted":0,"volume":16353600,"delay":0,"premium":"-52.71"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2608378618","title":"A Look At InnoCare Pharma (SEHK:9969) Valuation As It Targets First Profit On 2025 Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2608378618","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608378618?lang=en_us&edition=fundamental","pubTime":"2026-02-02 11:17","pubTimestamp":1770002277,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) is back in focus after the company projected an improvement in its 2025 financial performance, supported by stronger drug sales and an anticipated move into profitability for the first time.\nSee our latest analysis for InnoCare Pharma.\nThat profit outlook comes after a mixed share price run, with the latest close at HK$11.72. The 1 year total shareholder return of 111.93% contrasts with a 5 year total shareholder return decline of 44.06%. This suggests recent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-it-targets-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-as-it-targets-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"1193384375","title":"Zhitong Hong Kong Stock Morning Briefing | State Council Issues Plan to Accelerate New Growth Points in Service Consumption, Gold and Silver Plunge Overnight","url":"https://stock-news.laohu8.com/highlight/detail?id=1193384375","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193384375?lang=en_us&edition=fundamental","pubTime":"2026-01-30 07:09","pubTimestamp":1769728150,"startTime":"0","endTime":"0","summary":"The General Office of the State Council has issued the \"Work Plan for Accelerating the Cultivation of New Growth Points in Service Consumption.\" This plan aims to optimize and expand the supply of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06979","BK1161","VT","BK1574","BK4588","BK4585","09969","BK1192","AGQ"],"gpt_icon":1},{"id":"2607295702","title":"InnoCare Pharma Expects Turnaround to Profit in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2607295702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607295702?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:18","pubTimestamp":1769678339,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said it expects a turnaround to profit in 2025, according to a Hong Kong bourse filing Thursday.The firm expects 633 million yuan in attributable profit for the year, compared with a loss of 441 million yuan in 2024.Operating revenue is expected to rise 134% year-on-year to 2.37 billion yuan, the firm said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2606937862","title":"Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2606937862","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606937862?lang=en_us&edition=fundamental","pubTime":"2026-01-26 08:37","pubTimestamp":1769387871,"startTime":"0","endTime":"0","summary":"There wouldn't be many who think InnoCare Pharma Limited's ( HKG:9969 ) price-to-sales (or \"P/S\") ratio of 12.5x is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/pinning-down-innocare-pharma-limiteds-hkg9969-ps-is-difficul-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/pinning-down-innocare-pharma-limiteds-hkg9969-ps-is-difficul-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2601694118","title":"An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 45% Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2601694118","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601694118?lang=en_us&edition=fundamental","pubTime":"2026-01-06 08:54","pubTimestamp":1767660877,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, InnoCare Pharma fair value estimate is HK$23.47 Current share...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/an-intrinsic-calculation-for-innocare-pharma-limited-hkg9969","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/an-intrinsic-calculation-for-innocare-pharma-limited-hkg9969","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","FCF","09969","BK1574","BK1161","TV","BK4100","BK4211"],"gpt_icon":0},{"id":"1195454661","title":"INNOCARE (09969) Grants 1.4 Million Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1195454661","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195454661?lang=en_us&edition=fundamental","pubTime":"2025-12-31 17:20","pubTimestamp":1767172814,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) announced that on December 31, 2025, the company granted 1.4 million restricted share units to two grantees under the 2023 Equity Incentive Plan. This represents approximately 0.08% of the company's total issued share capital as of the date of this announcement.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09969","BK0239","688428"],"gpt_icon":0},{"id":"1101786163","title":"Guoyuan International Sets INNOCARE (09969) Target Price at HK$16.81 with \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1101786163","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101786163?lang=en_us&edition=fundamental","pubTime":"2025-12-24 15:08","pubTimestamp":1766560115,"startTime":"0","endTime":"0","summary":"Guoyuan International released a research report projecting INNOCARE's (09969) revenue for 2025-27 at RMB2.01 billion, RMB2.06 billion, and RMB2.56 billion, respectively, with net profits of RMB117...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK1161","09969","BK1574","BK0239"],"gpt_icon":0},{"id":"2593075124","title":"Is InnoCare Pharma (SEHK:9969) Quietly Recasting Its Future Around Autoimmune Dermatology?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593075124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593075124?lang=en_us&edition=fundamental","pubTime":"2025-12-21 18:12","pubTimestamp":1766311968,"startTime":"0","endTime":"0","summary":"Earlier this month, InnoCare Pharma received CDE approval in China to begin a Phase II/III trial of its novel TYK2 inhibitor soficitinib for chronic spontaneous urticaria, expanding its autoimmune and dermatology pipeline.\nThis move deepens InnoCare’s push beyond oncology into chronic inflammatory skin diseases, targeting a large, under-served CSU patient population in China that requires long-term treatment.\nWe’ll now examine how advancing soficitinib into Phase II/III for chronic...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-innocare-pharma-sehk9969-quietly-recasting-its-future-aro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/is-innocare-pharma-sehk9969-quietly-recasting-its-future-aro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"1148261323","title":"HK Stock Movement | INNOCARE (09969) Rises Over 4% as Self-Developed Novel TYK2 Inhibitor ICP-332 Gains Approval for Phase II/III Clinical Trials in CSU Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1148261323","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148261323?lang=en_us&edition=fundamental","pubTime":"2025-12-19 11:24","pubTimestamp":1766114688,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) surged more than 4%, reaching HK$13.69 by the time of writing, with a trading volume of HK$37.91 million. On December 18, the company announced via its official WeChat account that...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK4134","BK0239","III","688428","09969"],"gpt_icon":0},{"id":"2591692630","title":"InnoCare Pharma Receives Regulatory Approval to Begin Clinical Trial of Drug in Systemic Lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2591692630","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591692630?lang=en_us&edition=fundamental","pubTime":"2025-12-15 12:36","pubTimestamp":1765773407,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said it secured regulatory approval to begin a phase 3 clinical trial of orelabrutinib in systemic lupus erythematosus, according to a Hong Kong bourse filing Sunday.Shares of the pharmaceutical company fell nearly 2% in late morning trade Monday.The company plans to recruit the first patient in the study during the first quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2591898695","title":"InnoCare Pharma (SEHK:9969): Assessing Valuation After Landmark NTRK Solid-Tumor Approval for Zurletrectinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2591898695","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591898695?lang=en_us&edition=fundamental","pubTime":"2025-12-15 01:30","pubTimestamp":1765733420,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) just cleared a major milestone, with China’s regulator approving its next generation TRK inhibitor zurletrectinib for NTRK fusion positive solid tumors, the company’s first green light in solid cancers.\nSee our latest analysis for InnoCare Pharma.\nThe zurletrectinib approval lands after a volatile stretch, with InnoCare’s share price still up strongly this year thanks to a 150.79% year to date share price return. At the same time, the 90 day share price return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-assessing-valuation-after-landmark","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-assessing-valuation-after-landmark","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK1161","BK1574","09969","LARK"],"gpt_icon":0},{"id":"1188661956","title":"Innocare Pharma Limited (688428.SH): Orelabrutinib Meets Primary Endpoint in Phase IIb Study for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=1188661956","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188661956?lang=en_us&edition=fundamental","pubTime":"2025-12-14 16:30","pubTimestamp":1765701012,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (688428.SH) announced that its self-developed BTK inhibitor, orelabrutinib, has met the primary endpoint in a Phase IIb clinical study for treating systemic lupus...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","09969","BK1574","BK1161","688428"],"gpt_icon":0},{"id":"2591901655","title":"First Solid-Tumor Drug Approval Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591901655","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591901655?lang=en_us&edition=fundamental","pubTime":"2025-12-13 23:28","pubTimestamp":1765639712,"startTime":"0","endTime":"0","summary":"In the past week, InnoCare Pharma reported China NMPA approval of zurletrectinib (ICP-723) for NTRK fusion-positive solid tumors in patients aged 12 and above, alongside strong efficacy and safety data, while also showcasing extensive positive clinical results for orelabrutinib and mesutoclax at the ASH 67th Annual Meeting.\nThis marks InnoCare’s first approved solid-tumor therapy, adding a blood–brain-barrier-penetrant TRK inhibitor to its portfolio and underscoring its push to build a broad...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/first-solid-tumor-drug-approval-might-change-the-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/first-solid-tumor-drug-approval-might-change-the-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","09969"],"gpt_icon":0},{"id":"1178739772","title":"HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1178739772","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178739772?lang=en_us&edition=fundamental","pubTime":"2025-12-12 14:10","pubTimestamp":1765519826,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09969","BK1161","BK0239","688428"],"gpt_icon":0},{"id":"1167601463","title":"Everest Medicines (01952) Announces Strategic Collaboration with Haisco; Silver Prices Hit Record High","url":"https://stock-news.laohu8.com/highlight/detail?id=1167601463","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167601463?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:31","pubTimestamp":1765495870,"startTime":"0","endTime":"0","summary":"**Key Highlights**   The Hang Seng Stock Connect Software & Semiconductor Index will be renamed the Hang Seng Stock Connect Software Theme Index, with methodology updates fixing constituent stocks at...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09863","BK1119","06099","BK1161","BK1589","BK1183","HK0000165453.HKD","BK1147","BK1564","09969","IE00BZ08YT58.USD","01952","01177","BK1574","02670","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","BK1191","BK1583"],"gpt_icon":0},{"id":"2590597224","title":"InnoCare Pharma Gets China Nod for Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597224","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597224?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:08","pubTimestamp":1765451311,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SHA:688428, HKG:9969) obtained approval for zurletrectinib from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.The drug is for the treatment of adult and adolescent patients with solid tumors harboring NTRK gene fusions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688428","BK1161","09969","BK1574","BK0239"],"gpt_icon":0},{"id":"1154080901","title":"InnoCare Pharma (09969) Releases Monthly Return for 30 November 2025, No Changes in Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1154080901","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154080901?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:11","pubTimestamp":1764839491,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Limited (09969) submitted its Monthly Return for 30 November 2025, showing that its authorized share capital remains unchanged at USD50,000, with a par value of USD0.000002 per share....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"gpt_icon":0},{"id":"2586466362","title":"InnoCare Pharma (SEHK:9969) Valuation in Focus After Revenue Growth and Narrowed Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2586466362","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586466362?lang=en_us&edition=fundamental","pubTime":"2025-11-27 12:38","pubTimestamp":1764218339,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) just released its latest earnings, reporting both higher revenue and a significantly smaller net loss for the nine months through September. These results are giving investors plenty to analyze right now.\nSee our latest analysis for InnoCare Pharma.\nFresh from reporting sharply reduced net losses and steadily rising revenue, InnoCare Pharma has enjoyed some serious momentum. Its share price has soared 160.98% year-to-date, and over the past year, investors have...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-valuation-in-focus-after-revenue-gr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-valuation-in-focus-after-revenue-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2583466822","title":"Earnings Update: InnoCare Pharma Limited (HKG:9969) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2583466822","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583466822?lang=en_us&edition=fundamental","pubTime":"2025-11-16 08:49","pubTimestamp":1763254163,"startTime":"0","endTime":"0","summary":"Investors in InnoCare Pharma Limited ( HKG:9969 ) had a good week, as its shares rose 8.4% to close at HK$15.17...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/earnings-update-innocare-pharma-limited-hkg9969-just-reporte","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/earnings-update-innocare-pharma-limited-hkg9969-just-reporte","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969"],"gpt_icon":0},{"id":"2583651849","title":"InnoCare Pharma (SEHK:9969): Evaluating Valuation After Sales Growth and Pipeline Advances Spark Market Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651849","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583651849?lang=en_us&edition=fundamental","pubTime":"2025-11-14 01:17","pubTimestamp":1763054273,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) just reported higher sales and a smaller net loss for the first nine months of 2025, while also advancing key drug candidates in its clinical pipeline. This combination is catching investor attention.\nSee our latest analysis for InnoCare Pharma.\nMomentum has returned in a big way for InnoCare Pharma, with its share price rallying 5.08% over the past week and boasting a striking year-to-date gain of 165.38%. Even after a pullback in the last quarter, the total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-evaluating-valuation-after-sales-gr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-evaluating-valuation-after-sales-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","09969"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0368},{"period":"1month","weight":-0.0992},{"period":"3month","weight":-0.2014},{"period":"6month","weight":-0.3617},{"period":"1year","weight":1.0215},{"period":"ytd","weight":-0.0846}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0699},{"period":"1year","weight":0.3273},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.5,"avgChangeRate":0.11712},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"INNOCARE","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOCARE,09969,INNOCARE股票,INNOCARE股票老虎,INNOCARE股票老虎国际,INNOCARE行情,INNOCARE股票行情,INNOCARE股价,INNOCARE股市,INNOCARE股票价格,INNOCARE股票交易,INNOCARE股票购买,INNOCARE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}